Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms in African Americans and Latinos: Treatment in the Context of Common Comorbidities

American Journal of Medicine

Volumn 121, Issue 8 SUPPL.2, 2008, Pages

  Colon, Ivan ^a   Payne, Richard E ^b  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b North Coast Family Medical Group   (United States)

Author keywords

African American; Benign prostatic hyperplasia; Comorbidities; Latino; Treatment options

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DARIFENACIN; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; OXYBUTYNIN; PHYTOSTEROL; PLACEBO; PYGEUM AFRICANUM EXTRACT; SABAL EXTRACT; SOLIFENACIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN; TOLTERODINE;

AFRICAN AMERICAN; ARTICLE; ASTHENIA; CARDIOVASCULAR DISEASE; COMORBIDITY; DIABETES MELLITUS; DISEASE SURVEILLANCE; DIZZINESS; EJACULATION DISORDER; ERECTILE DYSFUNCTION; ETHNICITY; GENETIC VARIABILITY; HIGH INTENSITY FOCUSED ULTRASOUND; HISPANIC; HUMAN; HYPERTENSION; INSULIN RESISTANCE; KIDNEY FAILURE; LOWER URINARY TRACT SYMPTOM; METABOLIC DISORDER; METABOLIC SYNDROME X; MONOTHERAPY; ORTHOSTATIC HYPOTENSION; PHYTOTHERAPY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RACE; RISK ASSESSMENT; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; SEXUAL HEALTH; SOCIOECONOMICS; SYNCOPE; TRANSURETHRAL INCISION OF THE PROSTATE; TRANSURETHRAL RESECTION; TREATMENT PLANNING; UNITED STATES;

ADRENERGIC ALPHA-ANTAGONISTS; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; AZASTEROIDS; COMORBIDITY; ENZYME INHIBITORS; HISPANIC AMERICANS; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; SEVERITY OF ILLNESS INDEX; TRANSURETHRAL RESECTION OF PROSTATE; URINATION DISORDERS;

EID: 48149088143     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2008.05.023     Document Type: Article

References (68)

1. Chute C.G., Panser L.A., Girman C.J., et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 150 (1993) 85-89
2. Welch G., Weinger K., and Barry M.J. Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study. Urology 59 (2002) 245-250
3. Sarma A.V., McLaughlin J.C., Jacobsen S.J., et al. Health-seeking behavior and lower urinary tract symptoms among a cohort of African-American men: the Flint Men's Health Study. Presented at the 2004 American Urological Association Annual Meeting, May 8-13, San Francisco, CA. Abstract 1547. http://www.abstracts2view.com/aua_archive/view.php?nu=2004005247 Accessed May 17, 2008
4. Sarma A.V., Wei J.T., Jacobson D.J., et al. Comparison of lower urinary tract symptom severity and associated bother between community-dwelling black and white men: the Olmsted County Study of Urinary Symptoms and Health Status and the Flint Men's Health Study. Urology 61 (2003) 1086-1091
5. Roehrborn C.G., Logie J.W., Blackman N., et al. Racial differences in the risk of BPH progression and prostate cancer. Presented at the 2004 American Urological Association Annual Meeting, May 8-13, San Francisco, CA. Abstract 1549. http://www.abstracts2view.com/aua_archive/view.php?nu=200793512 Accessed
6. Aoki Y., Arai Y., Maeda H., Okubo K., and Shinohara K. Racial differences in cellular composition of benign prostatic hyperplasia. Prostate 49 (2001) 243-250
7. Kaplan S.A., Reis R.B., Staiman V.B., and Te A.E. Is the ratio of transition zone to total prostate volume higher in African-American men than in their Caucasian or Hispanic counterparts?. Br J Urol 82 (1998) 804-807
8. Salam M.T., Ursin G., Skinner E.C., Dessissa T., and Reichardt J.K. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer. Urol Oncol 23 (2005) 246-253
9. Michel M.C., Heemann U., Schumacher H., Mehlburger L., and Goepel M. Association of hypertension with symptoms of benign prostatic hyperplasia. J Urol 172 (2004) 1390-1393
10. Hammarsten J., and Högstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press 8 (1999) 29-36
11. Hytrin [package insert] (2001), Abbott Laboratories, North Chicago, IL
12. Cardura [package insert] (2002), Pfizer Roerig, New York
13. 1-blockers for LUTS on the medical management of hypertension. 2001 American Urological Association Annual Meeting, June 2-7, Anaheim, CA. Abstract 1563. http://www.abstracts2view.com/aua_archive/ J Urol 2001 May;165(5 suppl):1-418. Accessed
14. Lindholm L.H., Carlberg B., and Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension?. A meta-analysis. Lancet 366 (2005) 1545-1553
15. Kramer H., Han C., Post W., et al. Racial/ethnic differences in hypertension and hypertension treatment and control in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Hypertens 17 (2004) 963-970
16. Van Dijk M.M., Skrekas T., Wijkstra H., et al. Lower urinary tract symptoms and sexual dysfunction: a confirmed association. Presented at the 2005 American Urological Association Annual Meeting, May 21-26, San Antonio, TX. Abstract 1292. http://www.abstracts2view.com/aua_archive/viewphp?nu=20054236 also in print J Urol 2005 Apr;173(4 suppl):1467. Accessed
17. Rosen R., Altwein J., Boyle P., et al. Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7). Eur Urol 44 (2003) 637-649
18. ALF-ONE Study Group, Nickel J.C., Elhilali M., and Vallancien G. Benign prostatic hyperplasia (BPH) and prostatitis: prevalence of painful ejaculation in men with clinical BPH. BJU Int. 95 (2005) 571-574
19. Barqawi A., O'Donnell C., Kumar R., Koul H., and Crawford E.D. Correlation between LUTS (AUA-SS) and erectile dysfunction (SHIM) in an age-matched racially diverse male population: data from the Prostate Cancer Awareness Week (PCAW). Int J Impot Res 17 (2005) 370-374
20. Parsons J.K., Carter H.B., Partin A.W., et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 91 (2006) 2562-2568
21. Hammarsten J., and Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 39 (2001) 151-158
22. McVary K. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int 97 suppl 2 (2006) 23-28
23. Hammarsten J., Hogstedt B., Holthuis N., and Mellström D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1 (1998) 157-162
24. Nandeesha H., Koner B.C., Dorairajan L.N., and Sen S.K. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta 370 (2006) 89-93
25. Berger A.P., Deibl M., Leonhartsberger N., et al. Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunction. BJU Int 96 (2005) 1073-1078
26. Ferrannini E., Gastaldelli A., Matsuda M., et al. Influence of ethnicity and familial diabetes on glucose tolerance and insulin action: a physiological analysis. J Clin Endocrinol Metab 88 (2003) 3251-3257
27. Harris M.I., Flegal K.M., and Cowie C.C. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 21 (1998) 518-524
28. Young B.A., Maynard C., and Boyko E.J. Racial differences in diabetic nephropathy, cardiovascular disease, and mortality in a national population of veterans. Diabetes Care. 26 (2003) 2392-2399
29. Young B.A., Maynard C., Reiber G., and Boyko E.J. Effects of ethnicity and nephropathy on lower-extremity amputation risk among diabetic veterans. Diabetes Care. 26 (2003) 495-501
30. Gonzalez R.R., and Kaplan S.A. First-line treatment for symptomatic benign prostatic hyperplasia: is there a particular patient profile for a particular treatment?. World J Urol 24 (2006) 360-366
31. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol. 170 (2003) 530-547
32. Gee W.F., Holtgrewe H.L., Blute M.L., et al. 1997 American Urological Association Gallup survey: changes in diagnosis and management of prostate cancer and benign prostatic hyperplasia, and other practice trends from 1994 to 1997. J Urol 160 (1998) 1804-1807
33. Harkaway R.C., and Issa M.M. Medical and minimally invasive therapies for the treatment of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 9 (2006) 204-214
34. Narayan P., O'Leary M.P., and Davidai G. Early efficacy of tamsulosin versus terazosin in the treatment of men with benign prostatic hyperplasia: a randomized, open-label trial. J Appl Res 5 (2005) 237-245
35. Caine M. The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy. J Urol 136 (1986) 1-4
36. 1-Adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol 171 (2004) 1029-1035
37. ALFORTI Study Group, van Kerrebroeck P., Jardin A., Laval K.U., and van Cargh P. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. Eur Urol. 37 (2000) 306-313
38. Flomax [package insert] (2005), Boehringer-Ingelheim Pharmaceuticals, Inc, Ridgefield, CT
39. 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br J Pharmacol 113 (1994) 723-728
40. Lowe F.C. Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect. Clin Ther 19 (1997) 730-742
41. Kaplan S.A., and Neutel J. Vasodilatory factors in treatment of older men with symptomatic benign prostatic hyperplasia. Urology 67 (2006) 225-231
42. European Tamsulosin Study Group, Buzelin J.M., Fonteyne E., Kontturi M., Witjes W.P., and Khan A. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). Br J Urol 80 (1997) 597-605
43. Avodart [package insert] (2005), GlaxoSmithKline, Research Triangle Park, NC
44. Proscar [package insert] (2004), Merck & Co, Whitehouse Station, NJ
45. Roehrborn C.G., Lukkarinen O., Mark S., Siami P., Ramsdell J., and Zinner N. Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5α-reductase inhibitor dutasteride: results of 4-year studies. BJU Int 96 (2005) 572-577
46. Lepor H., Williford W.O., Barry M.J., et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 335 (1996) 533-539
47. McConnell J.D., Roehrborn C.G., Bautista O.M., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2387-2398
48. Kaplan S.A., McConnell J.D., Roehrborn C.G., et al. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol 175 (2006) 217-220
49. Jaffe W.I., and Te A.E. Overactive bladder in the male patient: epidemiology, etiology, evaluation, and treatment. Curr Urol Rep 6 (2005) 410-418
50. Kaplan S.A., Roehrborn C.G., Rovner E.S., Carlsson M., Bavendam T., and Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 296 (2006) 2319-2328
51. Athanasopoulos A., Gyftopoulos K., Giannitsas K., Fisfis J., Perimenis P., and Barbalias G. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 169 (2003) 2253-2256
52. Lee J.Y., Kim H.W., Lee S.J., Koh J.S., Suh H.J., and Chancellor M.B. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 94 (2004) 817-820
53. Bent S., Kane C., Shinohara K., et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med 354 (2006) 557-566
54. Wilt T.J., Ishani A., Stark G., MacDonald R., Lau J., and Mulrow C. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 280 (1998) 1604-1609
55. Ishani A., MacDonald R., Nelson D., Rutks I., and Wilt T.J. Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis. Am J Med 109 (2000) 654-664
56. Donkervoort T., Sterling A., van Ness J., and Donker P.J. A clinical and urodynamic study of tadenan in the treatment of benign prostatic hypertrophy. Eur Urol 3 (1977) 218-225
57. Chatelain C., Autet W., and Brackman F. Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: a randomized, double-blind study, with long-term open label extension. Urology 54 (1999) 473-478
58. Tan A., Liao C., Mo Z., and Cao Y. Meta-analysis of holmium laser enucleation versus transurethral resection of the prostate for symptomatic prostatic obstruction. Br J Surg 94 (2007) 1201-1208
59. Alivizatos G., and Skolarikos A. Greenlight laser in benign prostatic hyperplasia: turning green into gold. Curr Opin Urol 18 (2008) 46-49
60. Patel A., Fuchs G.J., Gutierrez-Acéves J., and Andrade-Perez F. Completeness and efficiency of prostate tissue removal: loop resection compared with a new operative technique of transurethral electrovaporization. BJU Int 84 (1999) 43-49
61. Liu C.K., Lee W.K., Ko M.C., Jeng H.S., Chiang H.S., and Yu H.J. Transurethral RollerLoop vapor resection of prostate for treatment of symptomatic benign prostatic hyperplasia: a 2-year follow-up study. Scand J Urol Nephrol 40 (2006) 409-415
62. Ho H.S., and Cheng C.W. Bipolar transurethral resection of prostate: a new reference standard?. Curr Opin Urol 18 (2008) 50-55
63. Hill B., Belville W., Bruskewitz R., et al. Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial. J Urol 171 (2004) 2336-2340
64. Gupta N., Sivaramakrishna, Kumar R., Dogra P.N., and Seth A. Comparison of standard transurethral resection, transurethral vapour resection and holmium laser enucleation of the prostate for managing benign prostatic hyperplasia of >40 g. BJU Int. 97 (2006) 85-89
65. Platz E.A., Kawachi I., Rimm E.B., Willett W.C., and Giovannucci E. Race, ethnicity and benign prostatic hyperplasia in the Health Professionals Follow-up Study. J Urol 163 (2000) 490-495
66. Collins M.F., Friedman R.H., Ash A., Hall R., and Moskowitz M.A. Underdetection of clinical benign prostatic hyperplasia in a general medical practice. J Gen Intern Med 11 (1996) 513-518
67. Roehrborn C.G., McConnell J., Jacobs S., et al. Baseline prostate volume and serum PSA predict rate of prostate growth: analysis of the MTOPS data. J Urol 169 suppl 4 (2003) 364 Abstract 1361
68. Slawin K.M., Levitt J.M., Lamb D.J., et al. Baseline serum BPH-A level enhances the accuracy of a nomogram to predict BPH progression in men enrolled on the GSK Phase III dutasteride trials. Presented at the 2006 American Urological Association Annual Meeting, May 20-25, Atlanta, GA. Abstract 1352. http://www.abstracts2view.com/aua_archive/view.php?nu=200696462 also in print J Urol 2006 Apr;175(4 suppl):1-554. Accessed